Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
2.
Anticancer Drugs ; 16(7): 747-9, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16027524

ABSTRACT

Brain metastases are a frequent finding in patients with non-small cell lung cancer (NSCLC). The present case reports the clinical course of a patient who was treated with gefitinib alone for progressive brain metastases after whole-brain irradiation treatment (WBRT). A 50-year-old women with primary stage IV NSCLC (bone metastases) developed brain metastases after 3 cycles of chemotherapy consisting of paclitaxel and carboplatin (CBDA). After completion of the WBRT, magnetic resonance imaging (MRI) indicated further progression. Two cycles of temozolomide and topotecan were applied; this was ineffective in preventing central nervous system progression. For symptomatic brain metastatic disease the patient received gefitinib as single-agent treatment. Within a few weeks of treatment there was an obvious clinical improvement. Follow-up of the brain 2 months after the start of treatment showed a decrease in both the size and number of brain metastases. Additional manifestations in the lungs and the skeletal system were re-assessed as stable disease during the treatment with gefitinib. Within 4 months of treatment there were no side-effects such as skin rash or any other systemic toxicity. Gefitinib may therefore have a role in the treatment of brain metastases from NSCLC.


Subject(s)
Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Quinazolines/therapeutic use , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Carcinoma, Non-Small-Cell Lung/radiotherapy , Carcinoma, Non-Small-Cell Lung/secondary , Chemotherapy, Adjuvant , Female , Gefitinib , Humans , Lung Neoplasms/pathology , Middle Aged
4.
Internist (Berl) ; 46(1): 30-8, 2005 Jan.
Article in German | MEDLINE | ID: mdl-15580461

ABSTRACT

The acute renal failure is characterized by a rapid deterioration of the renal function. In addition to the usual prerenal, intrinsic and postrenal causes of an acute renal failure distinct causes have to be considered for oncological patients. Factors imminent to the malignant disease, e. g. paraneoplastic syndromes or retroperitoneal bulks can account for an acute renal failure. Paraproteins as produced by a multiple myeloma are other possible causes for renal dysfunction. For some anticancer drugs nephrotoxicity is a potential side effect, in particular for cisplatin, methotrexate, ifosfamide and melphalan. A hemolytic uremic syndrome may be induced by mitomycin and gemcitabine. Extensive surgery can be associated with rhabdomyolysis and myoglobinuria and results in renal impairment. Treatment of a chemosensitive neoplasia with a highly effective regimen may result in a tumor lysis syndrome with hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia.


Subject(s)
Acute Kidney Injury/diagnosis , Acute Kidney Injury/therapy , Antineoplastic Agents/adverse effects , Neoplasms/diagnosis , Neoplasms/therapy , Acute Disease , Acute Kidney Injury/etiology , Antineoplastic Agents/therapeutic use , Emergency Medical Services/methods , Humans , Neoplasms/complications , Paraneoplastic Syndromes/diagnosis , Paraneoplastic Syndromes/therapy , Practice Guidelines as Topic , Practice Patterns, Physicians' , Treatment Outcome
6.
Onkologie ; 26(2): 120-4, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12771519

ABSTRACT

BACKGROUND: The local recurrence rate of colorectal cancer has been significantly reduced due to the use of combined radiochemotherapy. Despite this improvement regarding locally advanced tumour recurrences, the treatment strategy for pre-treated patients remains difficult and unresolved. PATIENTS AND METHODS: We analysed treatment and follow-up data of 14 patients with local recurrence of rectal cancer who were treated with radiation therapy (RT), chemotherapy (CT) and regional hyperthermia (RHT) from November 1997 to December 2001. Nine of these patients had received irradiation and CT (= pre-treated patients) in the past. For this group, 30.6-39.6 Gy RT, 5-fluorouracil (5-FU) as a continuous infusion over 5 days per week (350 mg/m(2)/24 h) combined with RHT twice a week was given. The 5 remaining patients (= not pre-treated) received conformal irradiation of 45 Gy with a boost between 9 and 14.4 Gy, combined with continuous infusion of 5-FU on days 1-4, and 29-33 (500 mg/m(2)/ 24 h), and RHT twice a week. Response to therapy was evaluated by means of computed tomography (CT) or magnetic resonance imaging (MRI) and by clinical follow-up. RESULTS: Among 13 evaluated cases, the overall objective response rate was 54% (5 complete responses, 2 partial responses). At mean follow-up of 13.9 months (range 5-32 months) 7 patients were alive. CONCLUSION: The therapeutic regimen appears to be active in the treatment of local recurrences of rectal cancer. Larger-scaled studies are needed to evaluate the potency of hyperthermia in this therapeutic strategy.


Subject(s)
Antimetabolites, Antineoplastic/administration & dosage , Fluorouracil/administration & dosage , Hyperthermia, Induced , Neoplasm Recurrence, Local/therapy , Radiotherapy, Conformal , Rectal Neoplasms/therapy , Chemotherapy, Adjuvant , Combined Modality Therapy , Disease Progression , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Infusions, Intravenous , Male , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Radiotherapy, Adjuvant , Rectal Neoplasms/mortality , Rectal Neoplasms/pathology , Retrospective Studies , Survival Rate , Treatment Outcome
7.
J Infect Dis ; 184(10): 1320-4, 2001 Nov 15.
Article in English | MEDLINE | ID: mdl-11679922

ABSTRACT

Mouse infection with murine cytomegalovirus (MCMV) is an established model for studying human cytomegalovirus infection. In this study, the relationship was analyzed between MCMV activity in organs of infected mice and the presence of infectious virus (viremia), viral genomes (DNAemia), or secreted virus-encoded proteins in the blood. For the latter, 2 recombinant viruses were constructed that encode for the hepatitis B virus surface antigen and the secreted alkaline phosphatase, respectively, as secreted marker proteins. The secreted markers correlated better with the infection in organs than DNAemia and viremia. The marker protein assays can serve as practical and sensitive tools for longitudinal monitoring of MCMV infection in individual mice.


Subject(s)
Herpesviridae Infections/virology , Muromegalovirus/isolation & purification , Viral Proteins/blood , Alkaline Phosphatase/blood , Animals , DNA, Viral/blood , Disease Models, Animal , Hepatitis B Antigens/blood , Hepatitis B Surface Antigens/blood , Herpesviridae Infections/blood , Immunocompromised Host , Mice , Mice, Inbred BALB C , Muromegalovirus/genetics , Polymerase Chain Reaction , Recombination, Genetic , Time Factors , Viremia , Viscera/virology
8.
Eur J Cancer ; 37(13): 1609-16, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11527685

ABSTRACT

The efficacy of thermochemotherapy in adult patients with primary, recurrent or inadequately resected non-metastatic high-risk soft-tissue sarcomas (STS) was assessed. 54 patients were prospectively treated with four cycles of etoposide, ifosfamide and doxorubicin (EIA) combined with regional hyperthermia (RHT) followed by surgery, another four cycles of EIA without RHT and external beam radiation. The objective response rate was 16% and at a median follow-up time of 57 months, the 4-year estimated rates of local failure-free survival (LFFS), distant metastasis-free survival (DMFS), event-free survival (EFS) and overall survival (OS) were 59% (95% confidence interval (CI) 45-73%), 59% (95% CI 44-73%), 26% (95% CI 14-38%) and 40% (95% CI 27-53%), respectively. OS was in favour of patients responding to neoadjuvant treatment (P=0.073). In comparison to a preceding phase II study including pre- and postsurgical thermochemotherapy (RHT-91), at a 4-year follow-up the RHT-95 study cohort showed an inferior LFFS rate (P=0.027), but this did not affect DMFS (P=0.558) or OS (P=0.126). Hence, postsurgical thermochemotherapy seems critical for local tumour control without affecting survival.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hyperthermia, Induced/methods , Sarcoma/therapy , Adult , Aged , Chemotherapy, Adjuvant/methods , Cohort Studies , Disease-Free Survival , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Ifosfamide/administration & dosage , Male , Middle Aged , Neoplasm Recurrence, Local/therapy , Pilot Projects , Prospective Studies , Radiotherapy, Adjuvant/methods , Risk Factors , Treatment Outcome
10.
FEBS Lett ; 459(1): 133-8, 1999 Oct 01.
Article in English | MEDLINE | ID: mdl-10508932

ABSTRACT

Complement receptor type 1 (CR1) has 30 modules in its extracellular portion. An understanding of structure-function relationships within CR1 is being assembled gradually from studies of overlapping protein fragments. A CR1 fragment corresponding to modules 16 and 17 was expressed recombinantly as a non-glycosylated protein and its stability and unfolding characteristics studied using biophysical techniques. The results were compared with data collected previously on a CR1 fragment encompassing modules 15, 16 and 17 which together constitute a C3b-binding site (Kirkitadze, M.D., Krych, M., Uhrin, D. , Dryden, D.T.F., Smith, B.O., Wang, X., Hauhart, R., Atkinson, J.P. and Barlow, P.N. (1999) Biochemistry 38, 7019-7031). Modules within CR1 were found to co-operate during unfolding. The folding, stability and flexibility of this protein is therefore likely to be a complex function, and not just the sum, of contributions from individual modules.


Subject(s)
Complement C3b/metabolism , Receptors, Complement/metabolism , Binding Sites , Calorimetry, Differential Scanning , Circular Dichroism , Complement C3b/chemistry , Guanidine/pharmacology , Magnetic Resonance Spectroscopy , Pichia , Protein Conformation , Protein Folding , Receptors, Complement/chemistry , Receptors, Complement/genetics , Spectrometry, Fluorescence
11.
Biochemistry ; 38(22): 7019-31, 1999 Jun 01.
Article in English | MEDLINE | ID: mdl-10353813

ABSTRACT

A segment of complement receptor type 1 (CR1) corresponding to modules 15-17 was overexpressed as a functionally active recombinant protein with N-glycosylation sites ablated by mutagenesis (referred to as CR1 approximately 15-17(-)). A protein consisting of modules 15 and 16 and another corresponding to module 16 were also overexpressed. Comparison of heteronuclear nuclear magnetic resonance (NMR) spectra for the single, double, and triple module fragments indicated that module 16 makes more extensive contacts with module 15 than with module 17. A combination of NMR, differential scanning calorimetry, circular dichroism, and tryptophan-derived fluorescence indicated a complex unfolding pathway for CR1 approximately 15-17(-). As temperature or denaturant concentration was increased, the 16-17 junction appeared to melt first, followed by the 15-16 junction, and module 17 itself; finally, modules 15 and 16 became denatured. Modules 15 and 16 adopted an intermediate state prior to total denaturation. These results are compared with a previously published study [Clark, N. S., Dodd, I, Mossakowska, D. E., Smith, R. A. G., and Gore, M. G. (1996) Protein Eng. 9, 877-884] on a fragment consisting of the N-terminal three CR1 modules which appeared to melt as a single unit.


Subject(s)
Peptide Fragments/chemistry , Receptors, Complement 3b/chemistry , Amino Acid Sequence , Calorimetry, Differential Scanning , Circular Dichroism , Molecular Sequence Data , Nuclear Magnetic Resonance, Biomolecular , Peptide Fragments/biosynthesis , Peptide Fragments/genetics , Peptide Fragments/isolation & purification , Pichia/genetics , Protein Conformation , Protein Folding , Receptors, Complement 3b/biosynthesis , Receptors, Complement 3b/genetics , Receptors, Complement 3b/isolation & purification , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Solutions , Spectrometry, Fluorescence , Thermodynamics
13.
Clin Exp Immunol ; 112(1): 27-33, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9566786

ABSTRACT

Complement receptor type one (CR1; CD35) binds and processes C3b and C4b opsonized immune complexes and regulates complement activation. We have characterized the epitopes of 13 previously reported and seven new MoAbs to human CR1. The MoAbs formed seven groups based on their reactivity with a panel of deletion forms of CR1. Seventeen of the MoAbs reacted with CR1 at more than one site, a consequence of its repetitive sequence. All five of the MoAbs recognizing epitopes in the nearly identical repeats 3, 10, and 17, as well as one MoAb which reacted with repeats 8 or 1/2 of 9 and 15 or 1/2 of 16, blocked cofactor activity for C3b. Knowledge of the repeats bearing the epitopes for these MoAbs should facilitate the further characterization of CR1.


Subject(s)
Antibodies, Monoclonal/immunology , Antibody Specificity , Epitope Mapping , Receptors, Complement 3b/immunology , Animals , CHO Cells , Cricetinae , Humans , Immunodominant Epitopes/immunology , Mice
14.
J Biol Chem ; 273(15): 8623-9, 1998 Apr 10.
Article in English | MEDLINE | ID: mdl-9535836

ABSTRACT

Two functionally distinct but homologous sites in complement receptor type 1 (CR1) (CD35) were further characterized by homologous substitution mutagenesis of two CR1 derivatives, each containing one site. In both sites, reducing negative and/or increasing positive charge augmented interaction with iC3/C3b and C4b, supporting a role of ionic forces in the binding reaction. In one case, substitution of Asp at the end of complement control protein repeat (CCP) 2 with an Asn transformed the protein, with negligible cofactor activity and iC3 binding, into a mutant with activities similar to native CR1. Consequently, this protein, one-fourth the size of CR1, is a therapeutic candidate for a complement inhibitor. Another important observation is that the residues between two CCPs contribute to activity, probably because they influence positioning of one CCP relative to the next. The initial characterization of the third CCP of an active site led to identification of three peptides necessary for binding. In line with earlier findings for the first two CCPs, interactions with iC3/C3b are similar but not identical to those with C4b, implying overlapping but distinct binding domains. Moreover, changes in cofactor activity usually, but not always, parallel alterations in binding, indicating that these two activities are separable. We also mapped epitopes for a blocking and a function enhancing monoclonal antibody. Their effects can be explained by epitope location. The first antibody binds near functionally important residues. The second may shield inhibitory (negatively charged) residues. These results represent a comprehensive analysis of the active sites of CR1, which is built of modules found in more than 50 mammalian proteins.


Subject(s)
Receptors, Complement 3b/chemistry , Receptors, Complement 3b/metabolism , Amino Acid Sequence , Amino Acid Substitution , Animals , Antibodies, Monoclonal , Binding Sites , COS Cells , Complement C3/metabolism , Complement C3b/metabolism , Epitopes , Kinetics , Molecular Sequence Data , Mutagenesis, Site-Directed , Polymerase Chain Reaction , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Sequence Alignment , Structure-Activity Relationship , Transfection
15.
J Immunol ; 157(3): 1242-7, 1996 Aug 01.
Article in English | MEDLINE | ID: mdl-8757632

ABSTRACT

The chimpanzee (Ch) E complement receptor type 1 (CR177) appears to be an alternatively spliced product of the Ch CR1 gene transcript. Its cDNA-derived amino acid sequence contains complement protein-repeating modules (CP) 1-6, 28, 29, and 30 in tandem and is 98.8% homologous to the corresponding regions of human (Hu) CR1. It differs from the C4b binding site of Hu CR1 only by two amino acids, Tyr for Ser37 in CP 1 and Asp for Gly79 in CP 2. However, in addition to binding C4b, Ch E binds C3b. As homologous substitution of one of these amino acids (Tyr for Ser37) was previously shown to not confer C3b binding, we reasoned that either single substitution of the other amino acid or a combination of the two amino acid changes would be required for C3b binding. To test this, using a truncated form of Hu CR1 that has a binding site only for C4b, we made these additional constructs. Single substitution of either amino acid did not affect the ligand binding or cofactor activity. However, the double substitution induced C3b binding and increased cofactor activity for C3b without changing the C4b-binding property. Of interest, these two amino acids are also found in the homologous positions of CP 9 and 16, which form part of the C3b binding site of Hu CR1. Thus, Ch E CR177, one-third of the size and with only a single ligand binding site, by acquiring key amino acid substitutions, binds C3b and C4b and functions analogous to Hu E CR1.


Subject(s)
Complement C3b/metabolism , Complement C4b/metabolism , Receptors, Complement 3b/metabolism , Amino Acid Sequence , Amino Acids/metabolism , Animals , Binding Sites , Humans , Molecular Sequence Data , Mutagenesis , Pan troglodytes , Receptors, Complement 3b/genetics , Structure-Activity Relationship
16.
Hybridoma ; 14(1): 29-35, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7768531

ABSTRACT

A monoclonal antibody (MAb), KuN241, recognized an antigen present on all monocytes, polymorphonuclear leukocytes (PMNs), B cells, and a subpopulation of T cells. Cell surface expression pattern and immunoprecipitation studies indicated the molecule recognized by KuN241 to be complement receptor 1 (CR1). This was confirmed by sequential immunoprecipitation using E11, a CR1-specific monoclonal, and by immunoprecipitation analysis of a truncated transfection product of CR1. In vivo activation of PBLs for 7 days with pokeweed mitogen (PWM) abrogated surface expression of CR1 on B cells. Overnight culture with phorbol 12-myristate 13-acetate (PMA) downregulated the expression of CR1 detected by KuN241 both on PMNs and monocytes. Addition of MAb KuN241 to purified PMN and monocytes resulted in a transient increase in intracellular calcium ([Ca2+]i). This was blocked by the Fab fragment of MAb KuFc79 directed against the Fc gamma receptor. Further, Fab fragment of KuN241 cross-linked with F(ab')2 goat anti-mouse Ig failed to increase [Ca2+]i levels. Taken together, these results suggested a novel mechanism for transmembrane signaling events by dual binding of KuN241, the Fab region to CR1 and the Fc region of Fc gamma RII.


Subject(s)
Antibodies, Monoclonal , Receptors, Complement 3b/immunology , Animals , B-Lymphocytes/immunology , Calcium/metabolism , Down-Regulation , Humans , In Vitro Techniques , Mice , Monocytes/immunology , Monocytes/metabolism , Neutrophils/immunology , Neutrophils/metabolism , Receptors, Complement 3b/genetics , Receptors, Complement 3b/metabolism , Receptors, IgG/metabolism , Signal Transduction , T-Lymphocyte Subsets/immunology
18.
J Biol Chem ; 269(18): 13273-8, 1994 May 06.
Article in English | MEDLINE | ID: mdl-8175757

ABSTRACT

The complement receptor type 1 (CR1; CD35), carrying 30 short consensus repeats (SCRs), has two sites. Site 1 contains SCR-1 and SCR-2 and binds C4b. Site 2 contains SCR-8 and SCR-9 and was reported to bind mainly C3b (Klickstein, L. B., Bartow, T. J., Miletic, V., Rabson, L. D., Smith, J. A., and Fearon, D. T. (1988) J. Exp. Med. 168, 1699-1717). For the functional analysis we used two constructs, each with one site. CR1-4, composed of eight and one-half initial SCRs, carries site 1, binds C4b, and is cofactor for C4b cleavage. CR1-4(8,9), obtained from CR1-4 by converting site 1 to site 2, binds iC3/C3b and, unexpectedly, C4b. It is a cofactor for cleavage of both ligands. Its cofactor activity for C4b cleavage is greater than that of site 1. Analysis of the mutants constructed by interchanging homologous peptides between the two sites identified no sequences necessary for cofactor activity other than those required for binding. In site 2, peptides important for both ligands were found. Some modifications of either site led to higher activity for both ligands. Thus the activity of complement regulators can be increased by changing a few amino acids within SCRs, an important step toward the generation of more effective inhibitors of complement activation. Knowledge of the active sites of CR1 should be applicable to other SCR-containing proteins and should provide insights into the evolution of these proteins.


Subject(s)
Receptors, Complement 3b/metabolism , Amino Acid Sequence , Binding Sites , Cell Line , Hydrolysis , Molecular Sequence Data , Mutagenesis, Site-Directed , Peptides/metabolism , Receptors, Complement 3b/genetics , Sequence Alignment
19.
Rheum Dis Clin North Am ; 18(4): 893-914, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1455049

ABSTRACT

The complement system, especially the early components of the classic pathway, are critically involved in immune complex processing. The deposition of clusters of complement component C3b on a target marks it for elimination, primarily through an interaction with complement receptors. Not surprisingly, total and partial deficiencies of certain complement components and C3b receptors are associated with rheumatic diseases, particularly systemic lupus erythematosus. This predisposition is explicable, based on the critical role complement plays in immune complex handling.


Subject(s)
Complement System Proteins/genetics , Rheumatic Diseases/genetics , Complement Factor B/genetics , Humans , Major Histocompatibility Complex/genetics , Receptors, Complement/genetics
20.
Curr Opin Immunol ; 4(1): 8-13, 1992 Feb.
Article in English | MEDLINE | ID: mdl-1596373

ABSTRACT

Recently, a number of exciting developments have increased our understanding of complement receptors. These advances include determination of the spatial organization of the short consensus repeat unit, analysis of active sites within short consensus repeats, downregulation in vivo of the complement system by a recombinant receptor, elucidation of the structure of mouse receptors and their relationship to human molecules, and the cloning of the human C5a receptor.


Subject(s)
Receptors, Complement , Amino Acid Sequence , Animals , Complement Activation , Consensus Sequence , Humans , Mice , Molecular Sequence Data , Protein Conformation , Receptors, Complement/biosynthesis , Receptors, Complement/genetics , Receptors, Complement/ultrastructure , Recombinant Proteins , Sequence Homology, Nucleic Acid , Signal Transduction , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...